Micromet, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2008 Financial Results

Saturday, May 3, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., May 2 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,today announced that it will host a conference call and audio webcast onThursday, May 8, 2008, at 9:00 am Eastern Time (3:00 pm Central European Time)to discuss its first quarter 2008 financial results. Micromet anticipatesreleasing its financial results at 7:00 am Eastern Time (1:00 pm CentralEuropean Time) on Thursday, May 8, 2008.

To participate in this conference call, dial 800-901-5218 (U.S.) or617-786-4511 (international), passcode: 79417745. The audio webcast can beaccessed at: www.micromet-inc.com in the investor relations section of thewebsite.

A replay of the call will be available from 11:00 am Eastern Time on May8, 2008 (5:00 pm Central European Time) through Thursday, May 15, 2008. Thereplay number is 888-286-8010 (U.S.) or 617-801-6888 (international),passcode: 99810027.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel,proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Four of its antibodies are currently in clinical trials,while the remainder of the product pipeline is in preclinical development.The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment ofpatients with acute lymphoblastic leukemia and in a phase 1 clinical trial forthe treatment of patients with non-Hodgkin's lymphoma. BiTE antibodiesrepresent a new class of antibodies that activate a patient's own cytotoxic Tcells, considered the most powerful "killer cells" of the human immune system,to eliminate cancer cells. Micromet is developing MT103 in collaboration withMedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTEantibody in clinical trials, and is being developed by Micromet in a phase 1clinical trial for the treatment of patients with lung and gastric cancer.The third clinical stage antibody is adecatumumab, also known as MT201, ahuman monoclonal antibody which targets epithelial cell adhesion molecule(EpCAM)-expressing solid tumors. Micromet is developing adecatumumab incollaboration with Merck Serono in a phase 1b clinical trial evaluatingadecatumumab in combination with docetaxel for the treatment of patients withmetastatic breast cancer. The fourth clinical stage antibody is MT293 whichis licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase1 clinical trial for the treatment of patients with cancer. In addition,Micromet has established a collaboration with Nycomed for the development andcommercialization of MT203, a human antibody neutralizing the activity ofgranulocyte/macrophage colony stimulating factor (GM-CSF), which has potentialapplications in the treatment of various inflammatory and autoimmune diseases,such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involverisks and uncertainties that could cause actual results to be materiallydifferent from historical results or from any future results expressed orimplied by such forward-looking statements. Factors that may cause actualresults to differ materially from any future results expressed or implied byany forward-looking statements include the risk that product candidates thatappeared promising in early research, preclinical studies or clinical trialsdo not demonstrate safety and/or efficacy in subsequent clinical trials, therisk that encouraging results from early research, preclinical studies orclinical trials may not be confirmed upon further analysis of the detailedresults of such research, preclinical study or clinical trial, the risk thatadditional information relating to the safety, efficacy or tolerability of ourproduct can

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store